ESHO-Pyrexar Award
PROF. LARS LINDNER
The European Society of Hyperthermic Oncology (ESHO) awarded its highest honor, the 33rd annual ESHO-Pyrexar Award to Prof. Lars Lindner of Ludwig-Maximilians University (LMU) in Munich for outstanding contributions to hyperthermic oncology and the corresponding scientific achievement.
As the leading center for clinical studies on hyperthermia, LMU has begun operation of the latest MR image-guided hyperthermia system at Grosshadern university hospital. In this department over 15,000 patients have been treated with deep regional hyperthermia, many of whom had soft tissue sarcoma tumors. Alongside a phase III clinical trial on the benefits of adding hyperthermia to chemotherapy already published in JAMA ONCOLOGY, LMU is also running the Hyperthermia European Adjuvant Trial (HEAT) study, a similar randomized phase III trial on pancreatic cancer.
Complete listing of clinical trials
Events
All Events- 46. Erlanger Weiterbildung Erlangen, Germany Mar. 06 – 07, 2020
- ECR (European Congress of Radiology) Vienna, Austria Mar. 11 – 15, 2020
- Sarkomkonferenz Berlin, Germany Mar. 19 – 21, 2020
- ESTRO 2020 (European Society for Radiotherapy and Oncology) Vienna, Austria Apr. 03 – 07, 2020
- 101. Deutscher Röntgenkongress Leipzig, Germany May 20 – 23, 2020
Interview
Prof. Dr. Gaipl
Prof. Udo Gaipl, Head of Radiation Immunobiology at the Department of Radiation Oncology in Erlangen, Germany, explains the special efficacy of immunotherapy and hyperthermia. He has published over 155 peer-reviewed papers on this topic and founded The Radiation Immunobiology Group, aiming to understand the immune functions of patients exposed to radio- or radiochemotherapy especially in combination with immunotherapy.
Hyperthermia
Technology
Paul Turner, CTO at Pyrexar Medical Corporation covers “Present and Future Hyperthermia Technology Evolution”.
Paul Turner has been developing hyperthermia and ablation heat treatment methods for more than 40 years, including RF phased array systems for deep non-invasive and invasive phased arrays.
